Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
29%(2 trials)

Phase Distribution

Ph phase_2
2
29%
Ph phase_1
1
14%
Ph phase_3
2
29%
Ph phase_4
2
29%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 32 (28.6%)
Phase 42 (28.6%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

NCT02434848
completedphase_2

Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.

NCT03627507
completedphase_3

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

NCT00652938
completedphase_4

Immunologic Memory (Supp. of ATN 024)

NCT00142753
completedphase_4

LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

NCT00240526
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02434848Phase 2

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

Completed
NCT03627507Phase 2

Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.

Completed
NCT00652938Phase 3

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Completed
NCT00142753Phase 4

Immunologic Memory (Supp. of ATN 024)

Completed
NCT00240526Phase 4

LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

Completed
NCT01349283Phase 3

Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns

Completed
NCT00354861Phase 1

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7